
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE reported a 13% year-over-year increase in product sales, rising from €144.6 million in 2023 to €163.3 million in 2024, contributing to a total revenue of €169.6 million for the same period, which reflects a 10% increase from €153.7 million in the previous year. The company has achieved accelerated FDA approval for its vaccine Ixchiq, targeting chikungunya, and projects sales of this vaccine to reach €3 million in 2024, with growth expectations to €250 million by 2029. Valneva anticipates that Ixchiq will generate significant revenue, estimating sales exceeding €100 million by the third year post-launch, in line with expectations for the overall chikungunya vaccine market to surpass $500 million annually.
Bears say
Valneva SE is adjusting its financial projections negatively, with a revised 2025 revenue estimate decreased to €185.0 million from €222.5 million, highlighting a significant reduction in expected cash flows. Additionally, the company's operating cash burn is set to be substantially lowered to less than $30 million in 2025, a stark contrast to over €60 million in 2024, indicating tight financial management challenges. This financial tightening is further emphasized by the downward adjustment of the 2025 EPS estimate to (€0.65) from (€0.53), reflecting deteriorating profitability expectations and reduced sales forecasts for key products like Ixchiq.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares